Notify me when Athyrium Capital Management, LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | 2 | $8,686,216 | $0 | -$22,229,850 | -$22,229,850 | BIOR, PBYI | 13F-HR | 12 Nov 2024, 09:35 |
| Q2 2024 | 3 | $33,539,393 | +$22,229,850 | -$54,102,860 | -$31,873,010 | COHERUS BIOSCIENCES INC, BIOR, PBYI | 13F-HR | 08 Aug 2024, 13:35 |
| Q1 2024 | 3 | $72,784,577 | $0 | -$2,839,226 | -$2,839,226 | Omeros Corp, BIOR, PBYI | 13F-HR | 16 May 2024, 11:23 |
| Q4 2023 | 3 | $68,826,290 | $0 | -$40,480,898 | -$40,480,898 | Omeros Corp, BIOR, PBYI | 13F-HR | 14 Feb 2024, 16:28 |
| Q3 2023 | 6 | $113,555,368 | +$20,652,293 | -$34,980,566 | -$14,328,273 | Omeros Corp, Biora Inc., BIOR, Omeros Corp, PBYI | 13F-HR | 14 Nov 2023, 16:32 |
| Q2 2023 | 7 | $154,146,384 | +$5,015,423 | -$129,138,967 | -$124,123,544 | Biora Inc., Omeros Corp, Omeros Corp, Paratek Pharmaceuticals Inc., RVLPQ | 13F-HR | 14 Aug 2023, 12:49 |
| Q1 2023 | 8 | $279,118,574 | +$9,694,850 | -$43,015,254 | -$33,320,404 | AMYT, Biora Inc., Omeros Corp, RVLPQ, Omeros Corp | Restatement | 16 May 2023, 09:02 |
| Q4 2022 | 11 | $237,928,239 | +$11,452,712 | $0 | +$11,452,712 | AMYT, Biora Inc., Omeros Corp, Omeros Corp, RVLPQ | 13F-HR | 14 Feb 2023, 16:03 |
| Q3 2022 | 11 | $267,004,000 | +$24,329,984 | -$8,001,802 | +$16,328,182 | Biora Inc., AMYT, CMAX, RVLPQ, Omeros Corp | 13F-HR | 14 Nov 2022, 16:14 |
| Q2 2022 | 11 | $237,754,000 | +$17,756,745 | $0 | +$17,756,745 | Biora Inc., AMYT, BIOR, Omeros Corp, Omeros Corp | 13F-HR | 15 Aug 2022, 16:54 |
| Q1 2022 | 10 | $281,299,000 | +$48,459,000 | -$7 | +$48,458,993 | Progenity Inc., AMYT, BIOR, CMAX, Omeros Corp | 13F-HR | 16 May 2022, 16:11 |
| Q4 2021 | 6 | $218,092,000 | +$131,048,252 | $0 | +$131,048,252 | AMYT, Progenity Inc., CMAX, RVLPQ, SCTL | 13F-HR | 14 Feb 2022, 16:23 |
| Q3 2021 | 4 | $157,650,000 | +$5,898,960 | $0 | +$5,898,960 | BIOR, AMYT, CMAX, SCTL | 13F-HR | 15 Nov 2021, 16:10 |
| Q2 2021 | 4 | $239,861,000 | +$83,442,064 | $0 | +$83,442,064 | BIOR, AMYT, CMAX, SCTL | 13F-HR | 16 Aug 2021, 16:19 |
| Q1 2021 | 3 | $197,779,000 | +$6,145,000 | $0 | +$6,145,000 | BIOR, AMYT, SCTL | 13F-HR | 17 May 2021, 16:14 |
| Q4 2020 | 2 | $207,540,000 | $0 | $0 | $0 | BIOR, AMYT | 13F-HR | 16 Feb 2021, 16:36 |
| Q3 2019 | 1 | $5,073,000 | $0 | $0 | $0 | KALA | 13F-HR | 14 Nov 2019, 16:03 |
| Q2 2019 | 1 | $8,507,000 | $0 | -$86,826,000 | -$86,826,000 | KALA | 13F-HR | 14 Aug 2019, 16:06 |
| Q1 2019 | 2 | $97,853,000 | $0 | -$8,071,000 | -$8,071,000 | AEGERION PHARMACEUTICALS INC, KALA | 13F-HR | 15 May 2019, 16:14 |
| Q4 2018 | 3 | $103,805,000 | +$6,520,000 | -$28,635,177 | -$22,115,177 | AEGERION PHARMACEUTICALS INC, PTC THERAPEUTICS INC, KALA | 13F-HR | 12 Feb 2019, 16:41 |
| Q3 2018 | 3 | $125,186,000 | +$27,799,515 | -$5,761,044 | +$22,038,471 | AEGERION PHARMACEUTICALS INC, PTC THERAPEUTICS INC, APEN | 13F-HR | 13 Nov 2018, 16:38 |
| Q2 2018 | 3 | $92,483,000 | $0 | -$62,944,821 | -$62,944,821 | AEGERION PHARMACEUTICALS INC, PTC THERAPEUTICS INC, APEN | 13F-HR | 14 Aug 2018, 16:39 |
| Q1 2018 | 4 | $163,302,000 | +$939,549 | -$14,670,000 | -$13,730,451 | AEGERION PHARMACEUTICALS INC, VIVUS INC, PTC THERAPEUTICS INC, APEN | 13F-HR | 15 May 2018, 16:33 |
| Q4 2017 | 5 | $169,055,000 | $0 | $0 | $0 | AEGERION PHARMACEUTICALS INC, VIVUS INC, PTC THERAPEUTICS INC, SUCAMPO PHARMACEUTICALS INC, APEN | 13F-HR | 14 Feb 2018, 10:34 |